TELA Bio, Inc. - TELA STOCK NEWS

TELA Bio announced positive outcomes from the BRAVO Study, showcasing a low recurrence rate of just 2.6% for ventral hernia repairs using OviTex 1S. The two-year study, published in Annals of Medicine and Surgery, involved 92 patients and demonstrated significant improvements in patient quality of life from as early as three months post-surgery. Despite a 38% surgical site occurrence rate among predominantly high-risk patients, the data supports OviTex's efficacy as a viable alternative to traditional synthetic meshes.

TELA Bio, a commercial-stage medical technology company, has announced its participation in two investor conferences. TELA’s management will present virtually at the H.C. Wainwright Annual Global Investment Conference on September 12, 2022, at 7:00 AM ET. Additionally, they will take part in the Lake Street BIG6 1x1 Conference on September 14, 2022. TELA Bio focuses on innovative soft-tissue reconstruction solutions that prioritize patient anatomy preservation. The company is committed to enhancing clinical outcomes while reducing reliance on synthetic materials.

TELA Bio, Inc. is set to participate in the Inaugural Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 8:30 AM ET. This commercial-stage medical technology company focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes by preserving the patient’s anatomy. Interested parties can access the live and archived webcast through the company’s investor relations page. TELA is committed to offering cost-effective technologies that leverage natural healing while minimizing reliance on synthetic materials.

TELA Bio, Inc. has successfully closed its public offering of 4,600,000 shares of common stock at $8.00 per share, generating gross proceeds of $36.8 million. This includes 600,000 shares from the underwriter's option. The proceeds will be utilized for working capital, research and development, and various corporate purposes. The offering was registered under Form S-3 with the SEC. Lake Street Capital Markets, LLC served as the sole book-running manager for this offering.

TELA Bio, Inc. has announced the pricing of its public offering of 4,000,000 shares of common stock at $8.00 per share, aiming for gross proceeds of $32 million. Additionally, the underwriter has a 30-day option to purchase up to 600,000 shares at the same price. The offering, set to close around August 18, 2022, will fund working capital, R&D, and potential acquisitions. The offering is registered under a previously established shelf registration effective since December 29, 2020.

TELA Bio, Inc. has announced the initiation of an underwritten public offering of its common stock. The offering may include an additional 15% of shares available for purchase by the underwriter. Proceeds will be allocated for working capital, research and development, and other corporate purposes. The offering is subject to market conditions and may not materialize as planned. Lake Street Capital Markets is the sole book-running manager for the offering. The registration statement for this offering was declared effective by the SEC on December 29, 2020.

TELA Bio reported a 38% revenue increase in Q2 2022, reaching $10.4 million, driven by strong demand for OviTex® products. The company secured a GPO contract with Premier Inc., enhancing market access, and highlighted positive clinical data from ongoing studies. However, gross profit margins declined to 63%, impacted by a one-time amortization charge. Operating expenses rose to $16.8 million, leading to a net loss of $12.7 million. Despite these challenges, the company expects 2022 revenue between $42 million and $45 million, indicating a potential growth of 43% to 53% year-on-year.

TELA Bio, a commercial-stage medical technology company, announced its participation in two investor conferences in August 2022. The management will present virtually at the Needham Med Tech & Diagnostics 1x1 Conference on August 15 and at the Canaccord Annual Growth Conference on August 11 at 2:00 PM ET. The company focuses on innovative soft-tissue reconstruction solutions, emphasizing patient anatomy preservation. Live webcasts of the presentations will be available on their official site.

TELA Bio, a commercial-stage medical technology company, shared promising results from two studies focusing on its OviTex Reinforced Tissue Matrix. The BRAVO study reported a 2.6% recurrence rate for ventral hernias after 24 months, while the ReBAR study indicated a 1.9% recurrence rate for inguinal hernias over the same period. Both studies demonstrate OviTex's effectiveness in enhancing surgical outcomes and quality of life. Results will be presented at the 2022 American Hernia Society Meeting in September.